Acutaas Chemicals Ltd logo

Acutaas Chemicals Ltd

ACUTAAS NSE

Ami Organics Limited is one of the leading research and development-driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API) for New Chemical Entities, and materials for agrochemicals and fine chemicals.[1]

AI Verdict: HOLD Confidence: 5%

Acutaas Chemicals delivers exceptional profit growth of 62% CAGR over 3 years and is almost debt-free, but trades at a steep PE of 72x and 16.1x book value, making the risk-reward asymmetric at current levels. The 187% stock price rally in the last year has likely front-loaded much of the near-term upside.

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹26,917 Cr
Volatility
Moderate
P/E Ratio
75.84
EBITDA
₹480 Cr
Return on Equity
14.02%
Debt to Equity
0.12
Book Value
₹201.97
EPS
₹15.13
52W High
₹3,444.3
52W Low
₹1,059

Technical Indicators

Key Insights

Strengths

3
  • Company is almost debt free.
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 45.8% CAGR over last 5 years

Weaknesses

2
  • Stock is trading at 16.2 times its book value
  • Promoter holding has decreased over last 3 years: -6.75%

Growth Rate

Revenue Growth
30.82% ↗
Net Income Growth
127.89% ↗
Cash Flow Change
-5.46% ↘
ROE
70.41% ↗
ROCE
52.45% ↗
EBITDA Margin (Avg.)
43.05% ↗

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 3d ago
HOLD
Risk high

Acutaas Chemicals delivers exceptional profit growth of 62% CAGR over 3 years and is almost debt-free, but trades at a steep PE of 72x and 16.1x book value, making the risk-reward asymmetric at current levels. The 187% stock price rally in the last year has likely front-loaded much of the near-term upside.

Bull Case 8
  • Compounded profit growth of 62% CAGR over 3 years signals strong earnings momentum and operating leverage
  • Company is almost debt-free, providing financial flexibility and lower risk during interest rate cycles
  • Sales growth of 30% CAGR over 3 years and 33% TTM indicates sustained demand and market share gains
  • ROE improved to 24% last year from an 18% 5-year average, showing improving capital efficiency
  • 87.5% of analyst ratings are Buy (7 out of 8 analysts), reflecting broad consensus on growth outlook
  • 5-year compounded profit CAGR of 45.8% demonstrates long-term earnings compounding ability
  • Market cap of Rs 26,046 Cr still leaves room for re-rating if growth sustains in specialty chemicals/healthcare segment
  • Expected to deliver a good upcoming quarter, suggesting near-term earnings catalyst
Bear Case 8
  • PE ratio of 72x is extremely elevated, pricing in multiple years of flawless execution with no margin of safety
  • Trading at 16.1x book value leaves significant downside risk if growth decelerates even modestly
  • Promoter holding has decreased by 6.75% over last 3 years, raising concerns about insider confidence
  • Stock has rallied 187% in 1 year, increasing probability of mean reversion or profit-booking correction
  • Dividend yield of just 0.05% offers virtually no downside protection or income support
  • ROE and ROCE data gaps (null values) limit full visibility into sustainable return on capital
  • No 52-week high/low data available (reported as 0), making technical risk assessment difficult
  • Small analyst coverage of only 8 total ratings increases information asymmetry and liquidity risk

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 7d ago
Neutral 1
  • SGM-Technical role resignation May 18

    Mr. Trilok Vasant Sontakke resigned as Senior General Manager – Technical Support Department effective May 15, 2026, citing personal reasons.

TL;DR: Limited recent news flow for Acutaas Chemicals. The only development is a mid-level managerial resignation for personal reasons, which does not signal operational distress. With no material positive or negative catalysts visible, the near-term outlook remains data-starved and investors should watch for further management changes or operational updates.

Quarterly Results

  Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales
186
154
172
166
225
177
247
275
308
207
306
393
433
Expenses
146
120
148
140
182
147
198
206
224
156
211
243
249
Operating Profit
41
34
25
27
43
30
49
69
85
51
95
151
184
OPM %
22%
22%
14%
16%
19%
17%
20%
25%
28%
25%
31%
38%
42%
Other Income
0
1
-30
3
1
1
8
2
6
16
10
5
11
Interest
1
1
1
3
2
4
0
1
1
1
1
1
1
Depreciation
3
4
4
4
5
6
7
6
7
8
8
10
10
PBT
37
31
-10
24
37
20
50
63
83
58
96
145
184
Tax %
26%
28%
71%
25%
31%
26%
25%
28%
24%
24%
25%
27%
27%
Net Profit
27
22
-17
18
26
15
38
45
63
44
72
106
134
EPS in Rs
3.73
2.71
-2.55
2.27
3.41
1.71
4.56
5.49
7.63
5.41
8.82
13.19
16.09
Figures in ₹ Crores

Profit & Loss

  Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
160
188
239
240
341
520
617
717
1,007
1,339
Expenses
137
157
196
198
260
415
493
589
775
859
Operating Profit
23
31
42
42
80
105
123
128
232
480
OPM %
14%
16%
18%
17%
24%
20%
20%
18%
23%
36%
Other Income
0
3
0
2
1
3
4
-25
17
42
Interest
3
3
5
6
6
6
2
6
6
3
Depreciation
1
2
3
4
4
10
12
16
27
36
PBT
19
28
35
35
72
91
112
82
216
483
Tax %
35%
35%
34%
21%
25%
21%
26%
41%
26%
26%
Net Profit
12
18
23
27
54
72
83
49
160
356
EPS in Rs
40.17
61.67
11.1
13.08
8.57
9.87
11.43
5.8
19.38
43.51
Div. Payout %
0%
0%
0%
0%
0%
15%
13%
26%
8%
6%
Figures in ₹ Crores

Balance Sheet

  Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
2
2
10
10
32
36
36
37
41
41
Reserves
37
56
72
101
135
486
558
637
1,269
1,613
Borrowings
27
44
54
59
137
1
4
217
13
36
Other Liabilities
43
54
77
61
110
136
169
205
227
295
Total Liabilities
109
155
213
232
413
659
767
1,096
1,549
1,984
Fixed Assets
28
32
79
85
186
205
259
427
570
745
CWIP
11
30
2
12
0
3
30
125
130
332
Investments
1
3
2
2
1
2
2
0
0
0
Other Assets
68
91
131
133
225
450
477
543
848
907
Total Assets
109
155
213
232
413
659
767
1,096
1,549
1,984
Figures in ₹ Crores

Cash Flow

  Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
29
8
15
27
28
-12
66
125
118
292
Investing
-19
-25
-21
-24
-101
-121
-33
-365
-224
-266
Financing
-7
15
6
0
72
140
-12
239
261
4
Net Cash Flow
3
-2
0
3
-1
8
20
-1
156
30
Free Cash Flow
10
-16
-7
6
-77
-46
-31
-190
-76
-36
CFO/OP
153
53
68
85
52
10
73
116
71
84
Figures in ₹ Crores

Ratios

  Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
83
97
116
86
129
115
136
105
105
99
Inventory Days
76
89
95
148
123
150
131
139
119
149
Days Payable
148
154
168
146
172
158
157
119
103
99
Cash Conversion Cycle
11
31
43
88
80
107
111
125
121
149
Working Capital Days
46
64
28
34
51
141
139
79
123
116
ROCE %
—
38%
34%
27%
33%
24%
21%
16%
20%
32%

Shareholding Pattern

As of Mar 2026
Promoters 32.66%
Public 23.21%
DIIs 19.60%
FIIs 19.48%
Others 5.03%
Government 0.01%
Total 99.99%
  Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024May 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters
49.71%
41.05%
41.05%
41.05%
41.05%
39.41%
39.41%
39.41%
39.41%
38.93%
39.91%
39.91%
39.07%
35.98%
35.97%
35.96%
35.96%
32.66%
32.66%
32.66%
32.66%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
7.16%
0.00%
8.97%
10.01%
12.92%
13.87%
15.52%
16.48%
16.94%
16.85%
16.67%
19.48%
DIIs
0.00%
4.85%
2.63%
4.44%
3.01%
3.28%
3.72%
3.63%
5.23%
5.94%
5.55%
6.81%
8.81%
14.81%
19.93%
20.24%
18.31%
22.38%
22.59%
21.70%
19.60%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
Public
0.00%
42.98%
46.69%
44.74%
44.74%
38.35%
38.64%
38.96%
37.44%
36.13%
27.13%
30.01%
28.79%
26.06%
24.72%
23.56%
24.19%
23.27%
22.79%
23.53%
23.21%
Others
50.29%
11.11%
9.62%
9.77%
11.19%
18.96%
18.23%
18.00%
17.92%
11.84%
27.41%
14.30%
13.33%
10.22%
5.51%
4.71%
5.05%
4.74%
5.10%
5.43%
5.03%
No. of Shareholders
0
28
1,38,182
97,547
93,922
87,044
85,563
78,786
70,352
72,897
83,344
95,784
92,721
90,329
93,394
95,756
1,14,060
1,19,890
1,08,664
1,10,363
1,12,939

Documents

Frequently Asked Questions about Acutaas Chemicals Ltd

What does Acutaas Chemicals Ltd do?
Ami Organics Limited is one of the leading research and development-driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API) for New Chemical Entities, and materials for agrochemicals...
Where is Acutaas Chemicals Ltd (ACUTAAS) listed?
Acutaas Chemicals Ltd is listed on the Indian stock exchanges. It is listed on NSE: ACUTAAS and BSE: 543349. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Acutaas Chemicals Ltd belong to?
Acutaas Chemicals Ltd operates in the Healthcare sector within the Pharmaceuticals & Biotechnology industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Acutaas Chemicals Ltd?
Acutaas Chemicals Ltd has a market capitalisation of approximately ₹26916.77 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Acutaas Chemicals Ltd?
The Price-to-Earnings (PE) ratio of Acutaas Chemicals Ltd is 75.84. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Acutaas Chemicals Ltd?
Over the past 52 weeks, Acutaas Chemicals Ltd has traded between a low of ₹1,059 and a high of ₹3,444.3. This range helps investors understand the stock's price volatility and recent trading levels.
Does Acutaas Chemicals Ltd pay dividends?
Yes, Acutaas Chemicals Ltd has a dividend yield of 0.05%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Acutaas Chemicals Ltd?
Acutaas Chemicals Ltd has a Return on Equity (ROE) of 14.02%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Acutaas Chemicals Ltd on Tapetide?
On Tapetide, you can view Acutaas Chemicals Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Ami Organics Limited is one of the leading research and development-driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API) for New Chemical Entities, and materials for agrochemicals and fine chemicals.[1]

Website amiorganics.com
CEO Mr. Nareshkumar Ramjibhai Patel
Employees 879
Listed 2021-09-14
Face Value ₹ 5
Issued Size 8,18,71,122

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List